| Type: | IVD Reagent |
|---|---|
| Accuracy: | Conformity Rate of 12 Negative Control: 100% |
| Detection Limitation: | 500 Copies /Ml |
| Cross-Reactivity: | No |
| CT Values: | ≤ 5.0% |
| Technology: | Real-Time Fluorescent PCR Amplification |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Septin9 gene is located q25.3, 17 with 17 exons, Septin9 proteins have multiple subtypes (e.g. SEPT9-vl, v2, v3, v4), associated with cell functions such as chromosome separation, DNA repair, migration, apoptosis, etc. Several studies confirm, The v2 subtype promoter region CpG island methylation of Septin9 gene are closely related to the occurrence and development of colorectal cancer.
This kit is used for qualitative detection of gene methylation in human peripheral blood plasma septin9 vitro. To deny or deny colonoscopy Examination of patients, can be used septin9 human gene methylation detection kit for detection. This product is used for clinical diagnosis of colorectal cancer, suitable for 30~80 years old.
By real-time fluorescent PCR amplification technology, the kit uses fluorescent labeled probes and detects the fluorescent strength from the reporter during the amplification to monitor the PCR products quantity. Both detection probes and internal standard probes have fluorescent reporter and quencher. They are differentiated by labels with different colored fluorescent and detected independently at different wave lengths. When the probes are intact, the reporter is near the quencher, so it is inhibited. With PCR amplification, the probes hybrid with the targeted sequence and are degraded due to the 5'-3'exonuclease activity of the polymerase, and the fluorescent reporter and the quencher are separated, so the fluorescent signal can be detected. By presetting the cycle time, every effective cycle will lead to the increase of the fluorescent strength.
| Reagent | Volume | Quantily |
| Buffer A | 900µL | ×1 tube |
| Buffer B | 100µL | ×1 tube |
| Negative Control | 400µL | ×1 tube |
| Positive Control | 400µL | ×1 tube |
1. Accuracy: Conformity rate of 12 Negative Control: 100%; Conformity rate of 5 Positive Control: 100%.
2. Detection limitation: 500 copies /mL.
3. Inclusiveness: The LOD and repeatability of virus samples from different regions will not change.
4. Cross-Reactivity: This product will not cross react with positive samples of prostate, breast, lung, chronic gastritis, and cardiovascular.
5. Interfering Substances Studies: Endogenous substances such as blood and mucus that may be present in throat swabs and sputum samples do not interfere with the test results of the kit; exogenous substances such as phenylephrine, oxymetazoline, sodium chloride, and beclomethasone, flunisolide, budesonide, mometasone, fluticasone, histamine hydrochloride, alpha-interferon, zanamivir, ribavirin, oseltamivir, peramid Wei, lopinavir, ritonavir, arbidol, levofloxacin, azithromycin, ceftriaxone, meropenem, tobramycin did not interfere with the test results. 6. Precision: using precision reference CV1 and CV2 for within-batch and between-batch detection, the coefficient of variation (CV) of their Ct values is ≤ 5.0%.
Founded in 2018, CAS-Envision is a high-tech start-up company held by Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.
CAS-Envision is committed to creating an operating system of semiconductor and biomedical interconnection, to provide unique one-stop technical solutions for lVD and biopharma.ceutical companies. The company has established three major business segments: One is POCT, including lmmunochromatography, molecular POCT, electrochemical detection). Second is ultra-sensitive detection, like digital PCR, single moleculeimmunity. Third is medical chips for brain-computer interface, sensor chip, medical SoC chip.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}